These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 15373056)

  • 21. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 22. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV fusion inhibitors.
    Pozniak A
    J HIV Ther; 2001 Nov; 6(4):91-4. PubMed ID: 11740409
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel therapies based on mechanisms of HIV-1 cell entry.
    Kilby JM; Eron JJ
    N Engl J Med; 2003 May; 348(22):2228-38. PubMed ID: 12773651
    [No Abstract]   [Full Text] [Related]  

  • 25. Reassessment of enfuvirtide's role in the management of HIV-1 infection.
    Marr P; Walmsley S
    Expert Opin Pharmacother; 2008 Sep; 9(13):2349-62. PubMed ID: 18710359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV fusion and its inhibition in antiretroviral therapy.
    Greenberg M; Cammack N; Salgo M; Smiley L
    Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clades of HIV: their origins and clinical significance.
    Stebbing J; Moyle G
    AIDS Rev; 2003; 5(4):205-13. PubMed ID: 15011999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-20: a model for novel anti-HIV drugs in development.
    Laurence J
    AIDS Read; 2002 Nov; 12(11):469-70. PubMed ID: 12494906
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV-1 drug-resistance and drug-dependence.
    Baldwin C; Berkhout B
    Retrovirology; 2007 Oct; 4():78. PubMed ID: 17961213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
    Clotet B; Raffi F; Cooper D; Delfraissy JF; Lazzarin A; Moyle G; Rockstroh J; Soriano V; Schapiro J
    AIDS; 2004 May; 18(8):1137-46. PubMed ID: 15166529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of HIV-infected patients with multidrug-resistant virus.
    Harris M; Montaner JS
    Curr HIV/AIDS Rep; 2004 Sep; 1(3):116-21. PubMed ID: 16091231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.
    Foy K; Bradley-Springer L; Kempner T; Stevens L; Gahagan L
    J Assoc Nurses AIDS Care; 2005; 16(2):2-12. PubMed ID: 16438121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV entry inhibitors.
    Esté JA; Telenti A
    Lancet; 2007 Jul; 370(9581):81-8. PubMed ID: 17617275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins.
    Debnath AK
    Curr Opin Investig Drugs; 2006 Feb; 7(2):118-27. PubMed ID: 16499281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fuzeon, first of the so-called "fusion inhibitor" drug in new class of AIDS treatments and its warnings].
    Hayashi T
    Nihon Rinsho; 2005 Jan; 63(1):173-82. PubMed ID: 15675339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.
    Malik T; Chauhan G; Rath G; Murthy RS; Goyal AK
    Drug Deliv; 2017 Nov; 24(1):608-621. PubMed ID: 28240046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case histories, magic bullets and the state of drug discovery.
    Drews J
    Nat Rev Drug Discov; 2006 Aug; 5(8):635-40. PubMed ID: 16883301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical safety and pharmacology trial.
    Mauck C; Thurman A; Schwartz J
    Curr Top Microbiol Immunol; 2014; 383():79-95. PubMed ID: 24173586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 40. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.